AzTrials
AzTrials

Ischemic StrokePRACTISENCT05355831

Patient-tailored Transcranial Direct Current Stimulation to Improve Stroke Rehabilitation

A study testing Active Transcranial Direct Current Stimulation in people with Ischemic Stroke and Upper Extremity Hemiparesis, run by Christina Kruuse at 3 sites in Denmark.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

In a double-blinded sham-controlled study the effect of patient-tailored transcranial direct current stimulation during rehabilitation training will be examined. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Ischemic Stroke, Upper Extremity Hemiparesis
What is being tested?
Active Transcranial Direct Current Stimulation
Type of treatment
Medical device
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
22 participants
Where
3 sitesDenmark
Study dates
28 Aug 2022to Dec 2024
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Patients - Inclusion Criteria:

  1. Age >18 years
  2. Ischemic stroke confirmed by clinical and imaging criteria
  3. Hemiparesis including reduced upper-extremity function
  4. Location of stroke either cortically involving middle cerebral artery or the anterior cerebral artery circulation or subcortical (involving thalamus, basal ganglia).
  5. NIHSS score >2 and <8
  6. Modified Rankin Scale (mRS) ≤ 3
  7. Index of stroke within 4 weeks of inclusion
  8. Signed informed consent

Patients - Exclusion Criteria:

  1. >50% stenosis of extra- or intracranial artery as well as vascular malformations or aneurisms detected by brain CT-angiography.
  2. Exclusively ischemic stroke in spine, pons, brainstem, medulla or cerebellum.
  3. History of seizures, epilepsy, anxiety, dementia alcohol- or drug abuse.
  4. Prior serious head injury or neurosurgery
  5. Frequent severe headaches or migraine.
  6. Pregnancy or breastfeeding
  7. Current use of neuro-receptor/transmitter modulating medication, or medication interfering with seizure threshold (such as antiepileptic medication, some antidepressants, anxiety medication, antihistamines, stimulant drugs for attention deficit hyperactivity disorder).
  8. Pacemaker, implantable cardiac device unit (ICD-unit), metal fragments or other materials implanted not compatible with MRI (see appendix B).
  9. Claustrophobia
  10. Prior adverse effect to TDCS or Transcranial Magnetic Stimulation.
  11. Not able to provide informed consent.
  12. Terminally ill or short life expectancy.

Healthy controls - Inclusion criteria:

  1. Age between >18 years (matched to patients)
  2. Sex and age matched to patients
  3. Able bodied
  4. Have the ability to comply with all requirements of the study protocol, as determined by the investigator
  5. No history of stroke or dementia
  6. Eligible for MRI and TMS

Healthy controls - Exclusion Criteria:

  1. History of neurologic disease
  2. History of cerebral haemorrhage or brain damage
  3. Pregnancy
  4. Pacemaker or other implanted electronic devices
  5. Claustrophobia
  6. Psychiatric disorder
  7. Epilepsy or close relatives suffering from epilepsy
  8. Migraine
  9. Any contraindication to MRI or TMS

Trial locations and contacts

3 sites in 1 country.

Christina Krusse, MD, Prof contact

+4538681233

christina.kruuse@regionh.dk

Mia Kolmos, MD contact

+4538681375

mia.kolmos@regionh.dk

Denmark3 sites, 3 recruiting
  • Copenhagen University Department of Nutrition and Exercise

    Copenhagen, 2200

    Anke Karabanov, MSc, PhD, +4535328039, anke@nexs.ku.dk

    Anke Karabanov, MSc, PhD

    Recruiting
  • Department of Neurology, Herlev Gentofte Hospital

    Herlev, 2730

    Christina Kruuse, MD, Prof, +4538681233

    Mia Kolmos, MD, +4538681375, mia.kolmos@regionh.dk

    Recruiting
  • Danish Research Centre for Magnetic Resonance

    Hvidovre, 2650

    Hartwig R Siebner, MD, Prof, +4538626541, hartwig.roman.siebner@regionh.dk

    Axel Thielscher, MSc, Prof, +4538623326, axelt@drcmr.dk

    Recruiting

Other trials in Denmark

About this study

In a double-blinded sham-controlled study the effect of patient-tailored transcranial direct current stimulation during rehabilitation training will be examined.

Read the detailed description

Approximately two thirds of stroke patients have reduced motor function which have a large impact on both activities of daily living and quality of life. Only 12-34% achieve full motor recovery.

There is a growing interest in using non-invasive brain stimulation (NIBS) techniques to supplement neurorehabilitation. NIBS can modulate cortical excitability and is a powerful tool for motor rehabilitation post-stroke. Application Transcranial Direct Current Stimulation (TDCS) is currently emerging as a tool used in neurorehabilitaiton. Prior studies have shown that TDCS-stimulation prior to physical training may significantly improve of motor function post-stroke. However, up to 50% of the participants recieving active TDCS show no response to stimulation.

A one-size-fits-all approach to TDCS in stroke rehabilitation may not be optimal and a more precise and individualized targeting is warranted to stimulate functionally relevant areas.

In this study TDCS will be personalized for stroke patients with upper-extremity paresis using individual functional and structural Magnetic Resonance Imaging (MRI) and an electric field modelling pipeline developed at Danish Research Centre for Magnetic Resonance (DRMCR). Based on these measures the electric current induced by TDCS will individually target the area with residual neural activity during movement. The effect of personalized TDCS will be assessed by clinical measures of motor improvement. Sub-studies furthermore assess if the functional reorganization of motor networks is affected by personalized TDCS by application of functional magnetic resonance (fMRI) and.

The study will have 3 phases:

  1. Personalization: The stimulation profile of each patient will be individualized using structural MRI a pipeline for simulation based on MRI (SimNIBS) to make individual anatomical head models in order to estimate the best montage and current dosage. Further, task-based fMRI will be used to estimate residual motor activity location. The target current is set in the area displaying the highest residual motor activity in sensorimotor areas.
  2. Intervention: Four weeks upper extremity training program of specialized supervised physiotherapeutic training 3 times per week. Each training session consists of 2x 20 minutes of training with concurrent personalized TDCS stimulation or montage of equipment but no stimulation (sham). Each bloc of 20 minutes training is separated by a small break of 5-10 minutes. Both patient, therapist and investigator will be blinded to the stimulation mode (activ TDCS or sham)
  3. Follow-up: Immediately after the 4 weeks of intervention and 12 weeks after intervention has ended, follow-up with clinical examination and brain MRI will be done.

Ad baseline Transcranial Magnetic Stimulation (TMS) will be done as well to assess corticospinal integrity as well as estimation of intracortical inhibition.

Hypothesis:

The main hypothesis is that personalized ipsi-lesional anodal TDCS during specialized individualized arm-training will lead to significantly greater improvements in upper-extremity motor function compared to sham.

Substudy with healthy controls:

A cohort of 20 healthy age- and sex matched controls will be recruited for one session of MRI and TMS identical to the procedure of the patients at baseline as well as the same questionnaires (Protocol amendment approved by the local Ethics Committee the 10th October 2022).

These data will be analyzed in a substudy for normative comparison between the stroke patients and healthy age- and sex-matched controls.

Hypothesis - Healthy Controls:

Stroke patients will exhibit a higher laterality index measured by fMRI and a stronger degree of interhemispheric inhibition at baseline compared to healthy controls measued by task-related fMRI and by TMS iSP and SICI.

The degree of interhemispheric inhibition in stroke patients will normalize during recovery and be similar to normal controls at the last follow-up after 12 weeks.

Further, the degree of normalization of the interhemispheric inhibition in stroke patients will be proportional to degree of improvement of the upper-extremity measured by UE-FMA.

July 2024:

Due to challenging recruitment and at much lower recruitment rate than expected the trial design was changed from superiority to pilot- and feasibility trial. Therefore, the sample size was correspondingly adjusted to expected 24 with 12 participants in each of the two arms. Furthermore, outcome measures were re-prioritized to also contain feasibility outcome measures and primary outcome was changed to follow-up Fugl-Meyer Assessment score of upper-extremity (FMA-UE) adjusted for baseline in stead of change in FMA-UE from baseline to follow-up.

Being tested
Active Transcranial Direct Current Stimulation, Sham stimulation
Keywords
non-invasive brain stimulation, transcranial direct current stimulation, effective connectivity, functional connectivity, Fugl-Meyer Assessment, Functional Magnetic Resonance Imaging
Medical subject headings
Ischemic Stroke

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Active Transcranial Direct Current StimulationDevice

    See arm/group description

  • Sham stimulationDevice

    See arm/group description

Study groups in NCT05355831
Study groupRoleWhat they receive
Active Transcranial Direct Current StimulationActive comparatorAnodal TDCS 1mV for 2x 20 minutes.
Receives: Device: Active Transcranial Direct Current Stimulation
Sham stimulationSham comparator2x 20 minutes of sham stimulation (30 sec ramp up, followed by current of 0 for 18.5 minutes followed by 30 sec ramp down).
Receives: Device: Sham stimulation

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Pilot outcome

    Difference in Upper-extremity Fugl-Meyer Assessment (UE-FMA) score at end of treatment. Range 0-66.

    Measured: From baseline to four months

Secondary outcomes (24)
  1. Change in upper-extremity function

    Difference in change in Action Reach Arm Test (ARAT) score. Range 0-57. High scores mean a better outcome.

    Measured: From baseline to four months

  2. Stroke severity

    Difference in change in National Health Institutes Stroke Scale (NIHSS). Range 0-42. High scores mean a better outcome.

    Measured: From baseline to four months

  3. Stroke disability

    Difference in change in Modified Rankin Scale (mRS). Range 0-6. Lower scores mean a better outcome.

    Measured: From baseline to four months

  4. ADL performance

    Difference in change in Bartel's 20-item Index (BI-20). Range 0-100. Higher scores mean better outcome.

    Measured: From baseline to four months

  5. Gait speed

    Difference in change in 10 Meter Walk Test (10MWT) in minutes:sec.

    Measured: From baseline to four months

  6. Physical Activity

    Difference in change in Physical Activity Scale 2.0 (PAS2). The answers will be translated into a Metabolic Equivalent of Task (MET)-score. The higher MET-score the higher level of activity.

    Measured: From baseline to four months

  7. Montreal Cognitive Assessment

    Difference in change in Montreal Cognitive Assessment (MoCA) score. Score range 0-30. Higher scores mean a better outcome.

    Measured: From baseline to four months

  8. Symbol Digit Modalities Test

    Difference in change in Symbol Digit Modalities Test (SDMT) score. Score range 0-110. Higher scores mean a better outcome.

    Measured: From baseline to four months

  9. Health-related quality of life

    Difference in change in EQ-5D-5L score. Range 1 to 20, a high score means low health-related quality of life. Includes a 0-100 visual analogue scale for overall percieved quality of life.

    Measured: From baseline to four months

  10. Becks Depression Inventory (BDI)

    Difference in change in BDI-II score. Score range 0-63. Higher score means increased risk of depression.

    Measured: From baseline to four months

  11. Fatigue Severity Scale (FSS)

    Difference in change in FSS score. Score range 0-7. Higher score means increased fatigue severity.

    Measured: From baseline to four months

  12. WHO-5 Well-Beeing Index

    Difference in change in WHO-5 score. Score range 0-100. Higher score means better quality of life.

    Measured: From baseline to four months

  13. Biomarker of inflammation and exercise

    Difference in change in serum level Cathepsin-B (unit mikro gram/L)

    Measured: From baseline to four months

  14. MRI - Cerebral bloodflow

    Change in cerebral blood flow measured with arterial spin labeling (ASL) during rest

    Measured: From baseline to four months

  15. fMRI - Effective connectivity

    Change in activation patterns measured with blood-oxygen-level dependent (BOLD) during both single and bimanual task.

    Measured: From baseline to four months

  16. fMRI - Interhemispheric inhibition

    Change in activation pattern measured by blood-oxygen-level dependent (BOLD) during both single and bimanual task.

    Measured: From baseline to four months

  17. fMRI - Laterality Index

    Change in activation pattern for hemispheric dominance measured by the ratio of active fMRI voxels in each hemisphere.

    Measured: From baseline to four months

  18. MRI - Corticospinal integrity

    Change in corticospinal integrity measured by diffusion MRI.

    Measured: From baseline to four months

  19. MRI - Infarct lesion load

    Difference in change in size of infarct lesion meaured by structural MRI.

    Measured: From baseline to four months

  20. Upper-extremity motor outcome

    Follow-up Upper-extremity Fugl-Meyer Assessment (UE-FMA) score adjusted for baseline. Range 0-66

    Measured: From baseline to four months

  21. Feasibility: TDCS sensations

    Proportion of participants experiencing sensations of TDCS (itching, pain, burning, vertigo, headache, fatigue, nausea, and/or other)

    Measured: During intervention

  22. Feasibility: Compliance to interventions

    Proportion of TDCS-intervention sessions attended out of the 12 planned sessions

    Measured: During intervention

  23. Feasibilitiy: Compliance to home-exercises

    Extent to which the participant has completed the planned home exercises ('fully', 'most', 'about 50%', 'below 50%', or 'not done')

    Measured: During intervention

  24. Feasibility: Patient feed-back

    The patients are asked if they would recommend TDCS to a peer patient (Yes/No)

    Measured: Follow-up1

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted2 May 2022
  2. Study start28 Aug 2022
  3. Primary completionAug 2024 (estimated)
  4. Study completionDec 2024 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Supportive care
Allocation
Randomised
Intervention model
Parallel groups
Model description
Intervention pilot- and feasibility trial
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
22 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05355831
Sponsor's protocol ID
H-20036199
Acronym
PRACTISE
Status last verified
Jul 2024
First submitted
26 Apr 2022
Last updated
11 Jul 2024
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: IPD can be accessed upon reasonable request and after evaluation from the investigator.

Questions about this trial

What is this clinical trial studying?

A study testing Active Transcranial Direct Current Stimulation in people with Ischemic Stroke and Upper Extremity Hemiparesis, run by Christina Kruuse at 3 sites in Denmark.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 11 Jul 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 3 sites in Denmark. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Christina Krusse, MD, Prof (+4538681233, christina.kruuse@regionh.dk), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Pilot outcome (time frame: From baseline to four months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Jul 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in